Alteri Wealth LLC Lowers Stock Position in Boston Scientific Corporation $BSX

Alteri Wealth LLC cut its position in shares of Boston Scientific Corporation (NYSE:BSX) by 6.7% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 9,401 shares of the medical equipment provider’s stock after selling 673 shares during the quarter. Alteri Wealth LLC’s holdings in Boston Scientific were worth $1,010,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the company. Bessemer Group Inc. boosted its stake in shares of Boston Scientific by 14,391.8% in the 2nd quarter. Bessemer Group Inc. now owns 2,919,801 shares of the medical equipment provider’s stock worth $313,618,000 after buying an additional 2,899,653 shares during the last quarter. Vanguard Group Inc. lifted its holdings in Boston Scientific by 1.9% during the second quarter. Vanguard Group Inc. now owns 137,134,110 shares of the medical equipment provider’s stock worth $14,729,575,000 after acquiring an additional 2,545,381 shares during the period. Price T Rowe Associates Inc. MD boosted its position in Boston Scientific by 18.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 10,610,487 shares of the medical equipment provider’s stock worth $1,070,387,000 after purchasing an additional 1,664,108 shares during the last quarter. Swedbank AB grew its stake in Boston Scientific by 114.5% in the 2nd quarter. Swedbank AB now owns 2,819,249 shares of the medical equipment provider’s stock valued at $302,816,000 after purchasing an additional 1,505,019 shares during the period. Finally, Goldman Sachs Group Inc. increased its position in shares of Boston Scientific by 10.8% during the 1st quarter. Goldman Sachs Group Inc. now owns 14,143,332 shares of the medical equipment provider’s stock valued at $1,426,779,000 after purchasing an additional 1,383,524 shares during the last quarter. 89.07% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. Wells Fargo & Company boosted their price target on shares of Boston Scientific from $124.00 to $125.00 and gave the stock an “overweight” rating in a report on Thursday, October 23rd. Leerink Partners boosted their target price on shares of Boston Scientific from $127.00 to $128.00 and gave the company an “outperform” rating in a research note on Wednesday, October 1st. Weiss Ratings restated a “buy (b-)” rating on shares of Boston Scientific in a research note on Wednesday, October 8th. UBS Group lifted their price target on shares of Boston Scientific from $135.00 to $140.00 and gave the stock a “buy” rating in a report on Thursday, October 23rd. Finally, Canaccord Genuity Group reissued a “buy” rating and set a $132.00 price objective on shares of Boston Scientific in a report on Thursday, October 23rd. Two analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $123.77.

Boston Scientific Price Performance

Boston Scientific stock opened at $99.23 on Wednesday. The firm has a market capitalization of $147.10 billion, a P/E ratio of 53.06, a PEG ratio of 2.02 and a beta of 0.58. Boston Scientific Corporation has a one year low of $85.98 and a one year high of $109.50. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82. The business has a fifty day moving average price of $99.41 and a 200-day moving average price of $102.51.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.71 by $0.04. Boston Scientific had a return on equity of 19.74% and a net margin of 14.43%.The company had revenue of $5.07 billion for the quarter, compared to analyst estimates of $4.97 billion. During the same period in the previous year, the company posted $0.63 EPS. The firm’s revenue for the quarter was up 20.3% compared to the same quarter last year. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. As a group, equities research analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current year.

Insider Transactions at Boston Scientific

In other news, Director Ellen M. Zane sold 12,891 shares of the stock in a transaction dated Thursday, November 6th. The shares were sold at an average price of $98.28, for a total value of $1,266,927.48. Following the sale, the director directly owned 24,134 shares of the company’s stock, valued at approximately $2,371,889.52. This represents a 34.82% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the business’s stock in a transaction that occurred on Monday, November 3rd. The shares were sold at an average price of $99.47, for a total transaction of $4,973,500.00. Following the transaction, the executive vice president directly owned 178,342 shares of the company’s stock, valued at approximately $17,739,678.74. This represents a 21.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 175,782 shares of company stock worth $17,742,314. Insiders own 0.50% of the company’s stock.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.